Current Neuro-Oncology
Volume
26 Number 26
20 November 2024
Home > Publications > Current Neuro-Oncology > Volume 26, Year 2024 > Number 26, 20 November
Cozzens JW, Lokaitis BC, Delfino K, Hoeft A, Moore BE, Fifer AS,
Amin DV, Espinosa JA, Jones BA, Acakpo-Satchivi L.
A
Phase 2 Sensitivity and Selectivity Study of High-Dose
5-Aminolevulinic Acid in Adult Patients Undergoing Resection of a
Newly Diagnosed or Recurrent Glioblastoma.
Oper
Neurosurg (Hagerstown). 2024 Nov 11. doi:
10.1227/ons.0000000000001417. PMID:
39526779. Interventional study˰
ˍ
Colliva C, Rivi V, Sarti P, Cobelli I, Blom JMC.
Exploring
Sex-Based Neuropsychological Outcomes in Pediatric Brain Cancer
Survivors: A Pilot Study.
Diseases. 2024 Nov
11;12(11):289. doi:
10.3390/diseases12110289. PMID:
39589963. Observational study. ˍ
*El-Hajj VG, Ranganathan S, Hoang H, Ghaith AK, Bydon M,
Elmi-Terander A.
The
impact of adjuvant radiotherapy on overall survival in spinal
low-grade gliomas: a propensity score-matched analysis.
J
Neurooncol. 2024 Nov 11. doi:
10.1007/s11060-024-04880-3. PMID:
39527384. Observational study. ˍ
Gdynia HJ, Schneiderat P, Gratzer A, Wiedhopf K, Gdynia N, Haase
I.
Clinical
features and rehabilitation outcome after surgical treatment of
spinal meningioma.
Spinal
Cord Ser Cases. 2024 Nov 11;10(1):75. doi:
10.1038/s41394-024-00688-5. PMID:
39528486. Observational study˰
ˍ
Kanamori M, Shibahara I, Shimoda Y, Akiyama Y, Beppu T, Ohba S,
Enomoto T, Ono T, Mitobe Y, Hanihara M, Mineharu Y, Ishida J,
Asano K, Yoshida Y, Natsumeda M, Nomura S, Abe T, Yonezawa H,
Katakura R, Shibui S, Kuroiwa T, Suzuki H, Takei H, Matsushita H,
Saito R, Arakawa Y, Sonoda Y, Hirose Y, Kumabe T, Yamaguchi T,
Endo H, Tominaga T.
Efficacy
and safety of carmustine wafers, followed by radiation,
temozolomide, and bevacizumab therapy, for newly diagnosed
glioblastoma with maximal resection.
Int
J Clin Oncol. 2024 Nov 11. doi:
10.1007/s10147-024-02650-9. PMID:
39527165. Interventional study.
ˍ
*Puranik AD, Dev ID, Rangarajan V, Jain Y, Patra S, Purandare NC,
Sahu A, Choudhary A, Bhattacharya K, Gupta T, Chatterjee A,
Dasgupta A, Moiyadi A, Shetty P, Singh V, Sridhar E, Sahay A, Shah
A, Menon N, Ghosh S, Choudhury S, Shah S, Agrawal A,
Lakshminarayanan N, Kumar A, Gopalakrishna A.
FET
PET to differentiate between post-treatment changes and recurrence
in high-grade gliomas: a single center multidisciplinary clinic
controlled study.
Neuroradiology.
2024 Nov 11. doi:
10.1007/s00234-024-03495-9. PMID:
39527264. Observational study. ˍ
*Wee CW, Lee JH, Lee HI, Kim J, Chang JH, Kang SG, Kim EH, Moon
JH, Cho J, Park CK, Kim CY, Hwang K, Yoon HI, Kim IA.
To
Use or Not to Use: Temozolomide in Elderly Patients with IDH
Wild-type MGMT Promoter Unmethylated Glioblastoma Treated with
Radiotherapy.
Cancer
Res Treat. 2024 Nov 11. doi:
10.4143/crt.2024.945. PMID:
39529389. Observational study. ˍ
Johnstad C, Reinertsen I, Thurin E, Dunås T, Bouget D,
Sagberg LM, Jakola AS, Solheim O.
The
prognostic importance of glioblastoma size and shape.
Acta
Neurochir (Wien). 2024 Nov 12;166(1):450. doi:
10.1007/s00701-024-06351-0. PMID:
39531176. Observational study. ˍ
Berghaus N, Hielscher T, Savran D,
Schrimpf D, Maas SLN, Preusser M, Weller M, Acker T, Herold-Mende
C, Wick W, von Deimling A, Sahm F.
Meningiomas:
Sex-Specific Differences and Prognostic Implications of a
Chromosome X Loss.
Neuro
Oncol. 2024 Nov
13:noae239. doi:
10.1093/neuonc/noae239. PMID:
39535060. Observational study; Laboratory investigation˰
ˍ
Bonaventure A, Simpson J, Kane E, Roman E.
Maternal
illnesses during pregnancy and the risk of childhood cancer: A
medical-record based analysis (UKCCS).
Int
J Cancer. 2024 Nov 13. doi:
10.1002/ijc.35166. PMID:
39535336. Observational study. ˍ
Monje M, Mahdi J, Majzner R, Yeom KW, Schultz LM, Richards RM,
Barsan V, Song KW, Kamens J, Baggott C, Kunicki M, Rietberg SP,
Lim AS, Reschke A, Mavroukakis S, Egeler E, Moon J, Patel S,
Chinnasamy H, Erickson C, Jacobs A, Duh AK, Tunuguntla R, Klysz
DD, Fowler C, Green S, Beebe B, Carr C, Fujimoto M, Brown AK,
Petersen AG, McIntyre C, Siddiqui A, Lepori-Bui N, Villar K, Pham
K, Bove R, Musa E, Reynolds WD, Kuo A, Prabhu S, Rasmussen L,
Cornell TT, Partap S, Fisher PG, Campen CJ, Grant G, Prolo L, Ye
X, Sahaf B, Davis KL, Feldman SA, Ramakrishna S, Mackall C.
Intravenous
and intracranial GD2-CAR T cells for H3K27M+
diffuse
midline gliomas.
Nature.
2024 Nov 13. doi:
10.1038/s41586-024-08171-9. PMID:
39537919. Interventional study.
ˍ
Petitt JC, Murayi R, El-Abtah ME, Momin A, Halima A, Potter T,
Ahorukomeye P, Jarmula J, Thapliyal M, Murphy ES, Chao ST, Suh JH,
Recinos PF, Kshettry VR.
Outcomes
of adjuvant radiation treatment following subtotal resection of
world health organization grade II meningiomas.
J
Neurooncol. 2024 Nov 13. doi:
10.1007/s11060-024-04878-x. PMID:
39538039. Observational study˰
ˍ
Hovman FR, Poulsen FR, Hansen S, Dahlrot RH.
The
risk of venous thromboembolism in adult patients with diffuse
glioma: a nationwide population-based study.
Acta
Oncol. 2024 Nov 14;63:887-892. doi:
10.2340/1651-226X.2024.40137. PMID:
39543846. Observational study. ˍ
Tini P, Cinelli E, Yavorska M, Donnini F, Marampon F, Pastina P,
Rubino G, Chibbaro S, Cerase A, Mazzei MA, Di Giacomo AM, Minniti
G.
Serum
lactate dehydrogenase as a prognostic marker for treatment
response in IDH wild-type glioblastoma patients undergoing stupp
protocol.
J
Neurooncol. 2024 Nov 14. doi:
10.1007/s11060-024-04862-5. PMID:
39540980. Observational study˰
ˍ
Atsukawa N, Tatekawa H, Ueda D, Oura T, Matsushita S, Horiuchi D,
Takita H, Mitsuyama Y, Baba R, Tsukamoto T, Shimono T, Miki Y.
Visualizing
the association between the location and prognosis of isocitrate
dehydrogenase wild-type glioblastoma: a voxel-wise Cox regression
analysis with open-source datasets.
Neuroradiology.
2024 Nov 15. doi:
10.1007/s00234-024-03503-y. PMID:
39542911. Observational study˰
ˍ
Hallal SM, Sida LA, Tűzesi CÁ, Shivalingam B, Sim HW,
Buckland ME, Satgunaseelan L, Alexander KL.
Size
matters: Biomolecular compositions of small and large
extracellular vesicles in the urine of glioblastoma patients.
J
Extracell Biol. 2024 Nov 15;3(11):e70021. doi:
10.1002/jex2.70021. PMID:
39554867. Laboratory investigation. ˍ
Han X, Xiao K, Bai J, Li F, Cui B, Cheng Y, Liu H, Lu J.
Multimodal MRI and 1H-MRS
for Preoperative Stratification of High-Risk Molecular Subtype in
Adult-Type Diffuse Gliomas.
Diagnostics
(Basel). 2024 Nov 15;14(22):2569. doi:
10.3390/diagnostics14222569. PMID:
39594235. Observational study. ˍ
*Inoue H, Kuroda JI, Fujioka Y, Hata N, Mizoguchi M, Yoshii D,
Sueyoshi H, Takeshima Y, Fujimoto K, Shinojima N, Sunami K, Mikami
Y, Nakamura H, Mukasa A.
Drug-resistant
BRAF V600E-mutant recurrent pleomorphic xanthoastrocytoma, CNS WHO
Grade 3 successfully resolved with incidental discontinuation of
combined BRAF and MEK inhibitor therapy.
Surg
Neurol Int. 2024 Nov 15;15:417. doi:
10.25259/SNI_734_2024. PMID:
39640311. Case report. ˍ
Näslund O, Jakobsson S, Thurin E, Skoglund T,
Pettersson-Segerlind J, Brynedal B, Jakola AS, Bartek J Jr.
Health-related quality of life in
surgically treated asymptomatic meningioma patients: A
population-based matched cohort study.
Neurooncol
Pract. 2024 Nov 15;11(6):723-732. doi:
10.1093/nop/npae047. PMID:
39554792. Observational study. ˍ
Pinchuk A, Tonchev N, Dumitru CA, Neyazi B, Stein KP, Sandalcioglu
IE, Rashidi A.
Risk of Postoperative
Hemorrhage After Glioma Surgery in Patients with Preoperative
Acetylsalicylic Acid.
Cancers
(Basel). 2024 Nov 15;16(22):3845. doi:
10.3390/cancers16223845. PMID:
39594800. Observational study. ˍ
Bai X, Xing H, Feng M, Ma W, Wang S.
Dose
and Efficacy of Bevacizumab in Recurrent High-Grade Gliomas: A
Retrospective Study.
Cancer
Manag Res. 2024 Nov 16;16:1617-1626. doi:
10.2147/CMAR.S481289. PMID:
39575164. Observational study. ˍ
Strauss JD, Gilbert MR, Mehta M, Li A, Ms RZ, Bondy ML, Sulman EP,
Yuan Y, Liu Y, Vera E, Wendland MM, Stieber VW, Puduvalli VK, Choi
S, Martinez NL, Robins HI, Hunter GK, Lin CF, Guedes VA, Richard
MA, Pugh SL, Armstrong TS, Scheurer ME.
Clinical
and Genetic Markers of Vascular Toxicity in Glioblastoma Patients:
Insights from NRG Oncology RTOG-0825.
Neuro
Oncol. 2024 Nov 16:noae234. doi:
10.1093/neuonc/noae234. PMID:
39549280. Observational study˰
ˍ
Singer S, Schranz M, Hippler M, Kuchen R, Weiß Lucas C,
Meixensberger J, Fehrenbach MK, Keric N, Mitsdoerffer M, Gempt J,
Coburger J, Kessler AF, Wehinger J, Misch M, Onken J, Rapp M, Voß
M, Nadji-Ohl M, Mehlitz M, Tatagiba M, Tabatabai G, Renovanz M.
Frequency and clinical associations of
common mental disorders in adults with high-grade glioma-A
multicenter study.
Cancer.
2024 Nov 17. doi: 10.1002/cncr.35653. PMID: 39550627.
Observational study. ˍ
Asioli S, Gatto L, Vardy U,
Agostinelli C, Di Nunno V, Righi S, Tosoni A, Ambrosi F, Bartolini
S, Giannini C, Franceschi E.
Immunophenotypic
Profile of Adult Glioblastoma IDH-Wildtype Microenvironment: A
Cohort Study.
Cancers
(Basel). 2024 Nov
18;16(22):3859. doi:
10.3390/cancers16223859. PMID:
39594814. Observational study.
ˍ
*Elia A, Roux A, Trancart B, Moiraghi A, Seneca M, Dezamis E,
Varlet P, Chretien F, Oppenheim C, Zanello M, Pallud J.
Watch-and-wait approach versus
adjuvant treatment after radical awake resection in selected
adult-type grade 3 gliomas, isocitrate
dehydrogenase mutant: A
case-matched cohort.
Neurooncol
Adv. 2024 Nov 18;6(1):vdae189. doi:
10.1093/noajnl/vdae189. PMID: 39620200.
Observational study. ˍ
Guo CC, Yang QY, Xi SY, Zhou J, Zhou ZH, Cao X, Liao YX, Li BX,
Dai XR, Wong M, Li YJ, Yu XH, Chen ZP.
Phase
I clinical study of a multi-kinase inhibitor TG02 capsule for the
treatment of recurrent high-grade gliomas with failed temozolomide
treatment in Chinese patients.
Chemotherapy.
2024 Nov 18:1-24. doi:
10.1159/000542365. PMID:
39557019. Interventional study˰
ˍ
Jimson D Jimenez M, Mohiuddin M, Li D, Ruge JR.
Treatment
of cerebral radiation necrosis using hyperbaric oxygen therapy in
a child: illustrative case.
J
Neurosurg Case Lessons. 2024 Nov 18;8(21):CASE24460.
doi:
10.3171/CASE24460. PMID:
39556802. Case report. ˍ
Sørensen MD, Olsen RFS, Burton M, Kavan S, Petterson SA,
Thomassen M, Kruse TA, Meyer M, Kristensen BW.
Microglia
induce an interferon-stimulated gene expression profile in
glioblastoma and increase glioblastoma resistance to
temozolomide.
Neuropathol
Appl Neurobiol. 2024 Nov 18;50(6):e13016. doi:
10.1111/nan.13016. PMID:
39558550. Laboratory investigation. ˍ
Vora S, Pafundi D, Voss M, Buras M, Ashman J, Bendok B, Breen W,
Hu L, Kizilbash S, Laack N, Liu W, Mahajan A, Mrugala M, Porter A,
Ruff M, Sio T, Uhm J, Yang M, Brinkmann D, Brown P.
Short-course
hypofractionated proton beam therapy, incorporating 18F-DOPA
PET and contrast-enhanced MRI targeting, for patients aged 65
years and older with newly diagnosed glioblastoma: a single-arm
phase 2 trial.
Lancet
Oncol. 2024 Nov 18:S1470-2045(24)00585-0. doi:
10.1016/S1470-2045(24)00585-0. PMID:
39571596. Interventional study˰
ˍ
Zhao D, Duan L, Juratli TA, Shen F, Zhou L, Cui S, Zhang H, Ren H,
Cheng L, Wang H, Shi W, Li T, Li M.
Comprehensive
multicentre retrospective analysis for predicting isocitrate
dehydrogenase-mutant lower-grade gliomas.
Ann
Clin Transl Neurol. 2024 Nov 18. doi:
10.1002/acn3.52251. PMID:
39556508. Observational study. ˍ
Karajannis MA, Onar-Thomas A, Lin T, Baxter PA, Boué DR,
Cole BL, Fuller C, Haque S, Jabado N, Lucas JT Jr, MacDonald SM,
Matsushima C, Patel N, Pierson CR, Souweidane MM, Thomas DL, Walsh
MF, Zaky W, Leary SES, Gajjar A, Fouladi M, Cohen KJ.
Phase
2 Trial of Veliparib, Local Irradiation and Temozolomide in
Patients with Newly Diagnosed High-Grade Glioma: A Children's
Oncology Group Study.
Neuro
Oncol. 2024 Nov 19:noae247. doi:
10.1093/neuonc/noae247. PMID:
39560182. Interventional study˰
ˍ
Krenzlin H, Jankovic D, Dauth A, Lange F, Wetzel M, Schmidt L,
Janssen I, Richter C, Stockinger M, Schmidberger H, Brockmann MA,
Sommer C, Meyer B, Keric N, Ringel F.
Multimodal
treatment of glioblastoma with multiple lesions - a multi-center
retrospective analysis.
J
Neurooncol. 2024 Nov 19. doi:
10.1007/s11060-024-04810-3. PMID:
39560695. Observational study. ˍ
Tabatabai G, Platten M, Preusser M, Weller M, Wick W, van den Bent
M.
Treatment of glioblastoma patients
with personalized vaccines outside clinical trials: Lessons
ignored?
Neuro
Oncol. 2024 Nov 19:noae225. doi:
10.1093/neuonc/noae225. PMID:
39561243. Comment. ˍ
REFERS
TO:
Latzer P, Zelba H, Battke F, Reinhardt A, Shao B,
Bartsch O, Rabsteyn A, Harter J, Schulze M, Okech T, Golf A,
Kyzirakos-Feger C, Kayser S, Pieper N, Feldhahn M, Wünsche J,
Seitz C, Hadaschik D, Garbe C, Hauser TK, la Fougère C,
Biskup D, Brooke D, Parker D, Martens UM, Illerhaus G, Blumenthal
DT, Merrell R, Lorenzo LS, Hidvégi M, de Robles P, Kebir S,
Li WW, Li VW, Williams M, Miller AM, Kesari S, Castro M,
Desjardins A, Ashley DM, Friedman HS, Wen PY, Neil EC, Iwamoto FM,
Sipos B, Geletneky K, Zender L, Glas M, Reardon DA, Biskup S.
A
real-world observation of patients with glioblastoma treated with
a personalized peptide vaccine.
Nat
Commun.
2024 Aug 11;15(1):6870. doi:
10.1038/s41467-024-51315-8. PMID:
39127809. Observational
study.
ˍ
Tang L, Chakravarti S, Li E, Mao Y, Ahmed AK, Mukherjee D.
Optimal treatment regimen for very
elderly patients with atypical meningioma: an analysis of survival
outcomes using the National Cancer Database (NCDB).
J
Neurooncol. 2024 Nov 19. doi:
10.1007/s11060-024-04886-x. PMID:
39560694. Observational study˰
ˍ
Calim Gurbuz B, Soylemez Akkurt T, Kusku Cabuk F, Sencan F, Tugcu
B, Ersen Danyeli A.
Olıgosarcoma:
A Rare Case Report Wıth Dıstınct Features.
Int
J Surg Pathol. 2024 Nov 20:10668969241291891. doi:
10.1177/10668969241291891. PMID:
39563510. Case report˰
ˍ
Hafez RFA, Fahmy OM, Hassan HT, Ganz JC.
Gamma
Knife Radiosurgery for symptomatic eloquently deep-seated cystic
pilocytic astrocytoma mural nodules: Retrospective case series of
effective outcomes.
Acta
Neurochir (Wien). 2024 Nov 20;166(1):466. doi:
10.1007/s00701-024-06366-7. PMID:
39565484. Observational study˰
ˍ
Turco L, Della Monica R, Giordano P, Cuomo M, Biazzo M, Mateu B,
Di Liello R, Daniele B, Normanno N, De Luca A, Rachiglio AM,
Chiaramonte C, Giugliano FM, Chiariotti L, Catapano G, Coretti L,
Lembo F.
Case report: Tracing in
parallel the salivary and gut microbiota profiles to assist
Larotrectinib anticancer treatment for NTRK
fusion-positive glioblastoma.
Front
Oncol. 2024 Nov 20;14:1458990. doi:
10.3389/fonc.2024.1458990. PMID:
39634265. Case report. ˍ